Samyang Holdings

Samyang Holdings strives to protect the health of all humankind. We are committed to ceaseless R&D and investment to offer a healthy lifestyle to human health worldwide and emerge as a biopharmaceutical company that leads innovation across the globe. We supply and develop medical devices and pharmaceutical products in various areas of medical treatment, including medical devices (MD) that utilize cutting-edge biodegradable materials, incrementally modified drugs and gene therapeutics, using unique and proprietary drug delivery systems (DDS) that will lead the future of medicine. Welcome to our website. I would like to first extend my sincere gratitude to our customers and partners for their unwavering loyalty and trust towards Samyang Holdings. Samyang Biopharmaceuticals Corporation began as the pharmaceutical business of Samyang Corporation back in 1995. It split off from Samyang Corporation in 2011 as Samyang Biopharm, which then in 2021 merged with Samyang Holdings, the holding company, with the aim to improve mid and long-term corporate values and become a global biopharmaceutical company. To fulfill the vision of "Healthcare value creator who improves the quality of life for patients," our business focus is within the areas of medical devices, pharmaceutical products, and gene therapeutics. In the medical device (MD) area, we have developed and commercialized polymer-based biodegradable sutures, which we are supplying globally. In the pharmaceutical product area, we have developed cytotoxic anti-cancer drugs for treating solid cancer and blood cancer that improve the survival rates of cancer patients. Our research focus in Gene Therapeutics is advancing drug delivery technology and exploring novel genetic therapy platforms with the aim to develop innovative therapeutics and vaccines. We moved our division including the R&D Center to Samyang Discovery Center located in Pangyo Techno Valley in 2016, and established Samyang Biopharm USA Inc. in Cambridge, MA in 2018 as a global networking hub for open innovation. Samyang Biopharm Hungary, our overseas production plant, opened in 2022, which is expected to further expand our business in the global medical device market. Samyang Biopharmaceuticals Corporation will leverage its R&D resources and implement global strategies to thrive as a global pharmaceutical company with innovative R&D capabilities. Thank you.